A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
UTAH MEDICAL PRODUCTS INC
UTMD
$218M
Mkt Cap
$67.14
+4.61%
UTAH MEDICAL PRODUCTS INC (UTMD) has a current P/E ratio of 19.0, compared to its historical median P/E of 19.5. The stock is currently considered Fair based on its historical valuation range.
UTAH MEDICAL PRODUCTS INC (UTMD) has a 5-year average return on invested capital (ROIC) of 24.1%. This indicates strong capital allocation and a potential competitive advantage.
UTAH MEDICAL PRODUCTS INC (UTMD) has a market capitalization of $218M. It is classified as a small-cap stock.
Yes, UTAH MEDICAL PRODUCTS INC (UTMD) pays a dividend with a trailing twelve-month yield of 1.83%. The company also returns capital through share buybacks, with a buyback yield of 3.84%.
Based on historical P/E analysis, UTAH MEDICAL PRODUCTS INC (UTMD) appears fair. The current P/E of 19.0 is 3% below its historical median of 19.5. The estimated fair value CAGR (P/E method) is 1.5%.
UTAH MEDICAL PRODUCTS INC (UTMD) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Currency amounts throughout this report are in thousands except per-share amounts and where noted. Utah Medical Products, Inc. (“UTMD” or “the Company”) is in the business of producing high quality cost- effective medical devices that are predominantly differentiated by safety and improved patient outcomes. Throughout this report, “UTMD” or “the Company” refers jointly to Utah Medical Products, Inc. and all of its corporate subsidiaries. Success depends on 1) recognizing and responding to needs of clinicians and patients, 2) rapidly designing or acquiring economical solutions that gain premarketing regulatory concurrence, 3) reliably producing devices that meet those clinical needs, and then 4) selling through a)UTMD's own direct channels into markets where the Company enjoys an established reputation and has a critical mass of sales and support resources, or b)relationship with other companies that have the resources to effectively distribute and support the Company's products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 39M | 39M | 41M | 50M | 52M | 49M |
| Net Income | 11M | 11M | 14M | 17M | 16M | 15M |
| EPS | $3.48 | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 |
| Free Cash Flow | 14M | 14M | 15M | 22M | 20M | 21M |
| ROIC | - | 7.4% | 9.2% | 36.9% | 36.8% | 29.9% |
| Gross Margin | 57.1% | 57.1% | 59.0% | 59.8% | 61.6% | 63.0% |
| Debt/Equity | 0.00 | - | - | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $1.23 | $1.23 | $1.22 | $1.18 | $0.87 | $3.13 |
| Operating Income | 11M | 11M | 14M | 17M | 20M | 19M |
| Operating Margin | 29.6% | 29.6% | 33.2% | 33.4% | 37.9% | 38.5% |
| ROE | 0.0% | - | - | 13.7% | 14.9% | 14.1% |
| Shares Outstanding | 3M | 3M | 4M | 4M | 4M | 4M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 41M | 40M | 39M | 41M | 42M | 47M | 42M | 49M | 52M | 50M | 41M | 39M | 39M |
| Gross Margin | 60.5% | 60.2% | 60.3% | 63.7% | 62.6% | 62.8% | 60.6% | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% | 57.1% |
| R&D | 460K | 522K | 475K | 447K | 454K | 483K | 486K | 526K | 493K | 560K | 813K | 668K | 668K |
| SG&A | 6.1M | 5.8M | 5.4M | 5.4M | 5.4M | 9.6M | 9.8M | 10M | 10M | 11M | 7.8M | 7.9M | 7.9M |
| EBIT | 16M | 16M | 16M | 19M | 19M | 18M | 14M | 19M | 20M | 17M | 14M | 11M | 11M |
| Op. Margin | 39.3% | 39.0% | 41.2% | 45.9% | 44.5% | 37.6% | 32.5% | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% | 29.6% |
| Net Income | 11M | 12M | 12M | 5.8M | 19M | 15M | 11M | 15M | 16M | 17M | 14M | 11M | 11M |
| Net Margin | 27.6% | 29.5% | 30.9% | 14.0% | 44.2% | 31.4% | 25.6% | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% | 29.3% |
| Non-Recurring | -35K | -1K | 5K | -17K | 410K | -16K | -1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 19.6% | 19.7% | 21.7% | 28.1% | 44.7% | 30.1% | 19.5% | 29.9% | 36.8% | 36.9% | 9.2% | 7.4% | N/A |
| ROE | 18.2% | 17.6% | 17.5% | 7.9% | 22.2% | 15.5% | 10.6% | 14.1% | 14.9% | 13.7% | N/A | N/A | 0.0% |
| ROA | 14.1% | 14.8% | 15.6% | 6.8% | 19.3% | 14.1% | 9.7% | 13.0% | 13.8% | 12.8% | 10.8% | 9.2% | 9.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 15M | 14M | 15M | 17M | 17M | 17M | 20M | 21M | 21M | 22M | 15M | 15M | 15M |
| Free Cash Flow | 14M | 14M | 11M | 15M | 16M | 17M | 19M | 21M | 20M | 22M | 15M | 14M | 14M |
| Owner Earnings | 15M | 13M | 14M | 16M | 16M | 10M | 13M | 14M | 14M | 16M | 12M | 11M | 11M |
| CapEx | 1.1M | 176K | 3.3M | 1.6M | 402K | 540K | 860K | 552K | 809K | 639K | 230K | 371K | 371K |
| Maint. CapEx | 637K | 619K | 610K | 660K | 765K | 6.8M | 7.2M | 7.3M | 7.0M | 6.3M | 2.8M | 3.0M | 3.0M |
| Growth CapEx | 473K | 0 | 2.7M | 937K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 637K | 619K | 610K | 660K | 765K | 6.8M | 7.2M | 7.3M | 7.0M | 6.3M | 2.8M | 3.0M | 3.0M |
| CapEx/OCF | 7.2% | 1.3% | 22.7% | 9.4% | 2.4% | 3.2% | 4.3% | 2.6% | 3.8% | 2.9% | 1.6% | N/A | 2.5% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 3.8M | 3.8M | 3.9M | 3.0M | 4.0M | 4.1M | 4.1M | 11M | 3.2M | 4.3M | 4.3M | 4.0M | 4.0M |
| Dividend Yield | 2.3% | 2.1% | 1.9% | 1308.1% | 1300.6% | 1.3% | 1.4% | 3.8% | 1.0% | 1.4% | 1.8% | N/A | 1.8% |
| Share Buybacks | 0 | 0 | 0 | 0 | 1.2M | 398K | 7.0M | 0 | 2.5M | 0 | 20M | 8.4M | 8.4M |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.4% | 0.1% | 2.4% | N/A | 0.8% | N/A | 9.4% | 0.0% | 3.8% |
| Stock-Based Comp | 74K | 87K | 92K | 129K | 64K | 113K | 160K | 166K | 183K | 225K | 256K | 373K | 373K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -15M | -23M | N/A | -40M | -51M | -42M | -51M | -61M | -75M | -92M | -82M | -85M | -85M |
| Cash & Equiv. | 19M | 23M | 26M | 40M | 51M | 43M | 52M | 61M | 75M | 93M | 83M | 86M | 86M |
| Long-Term Debt | 5K | 1K | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 295K | 282K | 225K | 225K |
| Debt/Equity | 0.06 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | N/A | N/A | 0.00 |
| Interest Coverage | 56.1 | 240.8 | N/A | N/A | N/A | N/A | 3427.0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 65M | 70M | 69M | 78M | 89M | 101M | 103M | 107M | 114M | 128M | N/A | N/A | 0 |
| Total Assets | 81M | 79M | 76M | 93M | 100M | 110M | 112M | 116M | 124M | 135M | 123M | 123M | 123M |
| Total Liabilities | 17M | 9.5M | 6.9M | 15M | 11M | 8.7M | 8.9M | 8.5M | 9.6M | 7.1M | N/A | N/A | N/A |
| Intangibles | 28M | 24M | 18M | 18M | 15M | 30M | 24M | 18M | 10M | 4.9M | 2.9M | 840K | 840K |
| Retained Earnings | 65M | 73M | 81M | 86M | 100M | 111M | 111M | 115M | 126M | 138M | 129M | 129M | 129M |
| Working Capital | 21M | 29M | 31M | 44M | 56M | 51M | 58M | 69M | 84M | 102M | 93M | 95M | 95M |
| Current Assets | 30M | 33M | 34M | 49M | 61M | 55M | 62M | 73M | 90M | 106M | 96M | 98M | 98M |
| Current Liabilities | 9.0M | 4.1M | 3.0M | 5.3M | 5.3M | 3.4M | 3.8M | 3.7M | 6.0M | 4.7M | 3.8M | 2.6M | 2.6M |
| Per Share Data | |||||||||||||
| EPS | 3.02 | 3.14 | 3.22 | 1,554.69 | 4,987.90 | 3.94 | 2.94 | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 | 3.48 |
| Owner EPS | 3.90 | 3.47 | 3.67 | 4,331.90 | 4,302.42 | 2.70 | 3.49 | 3.76 | 3.82 | 4.32 | 3.36 | 3.50 | 3.50 |
| Book Value | 17.13 | 18.47 | 18.38 | 20,994.89 | 23,922.58 | 27.05 | 28.00 | 29.27 | 31.35 | 35.25 | N/A | N/A | 0.00 |
| Cash Flow/Share | 4.08 | 3.66 | 3.86 | 4,543.94 | 4,525.27 | 4.56 | 5.48 | 5.79 | 5.80 | 6.12 | 4.23 | 4.53 | 4.39 |
| Dividends/Share | 1.00 | 1.02 | 1.04 | 794.14 | 1,082.26 | 1.10 | 1.12 | 3.13 | 0.87 | 1.18 | 1.22 | 1.23 | 1.23 |
| Shares Out. | 3.8M | 3.8M | 3.8M | 0.0M | 0.0M | 3.7M | 3.7M | 3.7M | 3.6M | 3.6M | 3.5M | 3.2M | 3.2M |
| Valuation | |||||||||||||
| P/E Ratio | 16.6 | 15.7 | 18.9 | 30.5 | 14.6 | 24.7 | 26.4 | 23.4 | 19.5 | 18.1 | 15.3 | N/A | 19.3 |
| P/FCF | 13.2 | 13.7 | 20.4 | 0.0 | 0.0 | 22.0 | 14.8 | 16.8 | 15.8 | 13.9 | 14.5 | N/A | 15.2 |
| EV/EBIT | 10.5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 12.4 | 9.5 | N/A | 11.6 |
| Price/Book | 2.9 | 2.7 | N/A | N/A | N/A | N/A | 2.8 | 3.2 | 2.8 | 2.3 | N/A | N/A | N/A |
| Price/Sales | 4.0 | 4.5 | 5.2 | 5.5 | 7.4 | 6.5 | 6.9 | 6.2 | 5.9 | 6.3 | 5.7 | N/A | 5.7 |
| FCF Yield | 7.6% | 7.3% | 4.9% | 5.9% | 6.1% | 4.5% | 6.8% | 6.0% | 6.3% | 7.2% | 6.9% | N/A | 6.6% |
| Market Cap | 189M | 186M | 230M | 259M | 272M | 364M | 285M | 346M | 322M | 301M | 212M | 0 | 218M |
| Avg. Price | 43.77 | 47.60 | 53.94 | 60.71 | 83.21 | 81.70 | 79.43 | 83.43 | 84.09 | 86.24 | 66.77 | 0.00 | 67.14 |
| Year-End Price | 50.13 | 49.32 | 60.94 | 69.51 | 72.43 | 97.43 | 77.55 | 94.57 | 88.30 | 82.62 | 60.59 | 0.00 | 67.14 |
UTAH MEDICAL PRODUCTS INC passes 6 of 9 quality checks, suggesting mixed fundamentals.
UTAH MEDICAL PRODUCTS INC trades at 19.0x trailing earnings, compared to its 15-year median P/E of 19.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 15.5x vs a median of 14.8x. The company's 5-year average ROIC is 24.1% with a gross margin of 60.1%. Total shareholder yield (dividends + buybacks) is 5.7%. At current prices, the estimated annualized return to fair value is +1.2%.
UTAH MEDICAL PRODUCTS INC (UTMD) reported annual revenue of $39 million in its most recent fiscal year, based on SEC EDGAR filings.
UTAH MEDICAL PRODUCTS INC (UTMD) has a net profit margin of 29.3%. This is a strong margin indicating high profitability.
UTAH MEDICAL PRODUCTS INC (UTMD) generated $14 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
UTAH MEDICAL PRODUCTS INC (UTMD) reported earnings per share (EPS) of $3.48 in its most recent fiscal year.
UTAH MEDICAL PRODUCTS INC (UTMD) has a 5-year average gross margin of 60.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for UTAH MEDICAL PRODUCTS INC (UTMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
No recent press releases.